First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
ALPACA is an interventional, multicentre, open-label, randomized active-controlled phase II
trial with two arms.
To estimate the treatment effect on overall survival, feasibility, efficacy and safety of
alternating treatment cycles of gemcitabine monotherapy followed by
nab-paclitaxel/gemcitabine relative to standard continuing nab-paclitaxel/gemcitabine cycles
in first-line treatment for metastatic pancreatic cancer in patients having received 3 cycles
of induction therapy with standard nab-paclitaxel/gemcitabine.